Repositioning Candidate Details
| Candidate ID: | R0308 |
| Source ID: | DB00852 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Pseudoephedrine |
| Synonyms: | (+) threo-2-(methylamino)-1-phenyl-1-propanol; (+)-(1S,2S)-Pseudoephedrine; (+)-Pseudoephedrine; (+)-psi-Ephedrine; (+)-threo-Ephedrine; d-Isoephedrine; d-Pseudoephedrine; d-psi-2-Methylamino-1-phenyl-1-propanol; d-psi-Ephedrine; Isoephedrine; L-(+)-Pseudoephedrine; L(+)-psi-Ephedrine; Pseudoephedrine; Pseudoephedrine D-form; Psi-ephedrin; Psi-ephedrine; trans-Ephedrine; ψ-ephedrine |
| Molecular Formula: | C10H15NO |
| SMILES: | CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Pseudoephedrine is structurally related to but exerts a weaker effect on the sympathetic nervous system. Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseudoephedrine was described in dogs in 1927. |
| CAS Number: | 90-82-4 |
| Molecular Weight: | 165.2322 |
| DrugBank Indication: | Pseudoephedrine is a sympathomimetic amine used for its decongestant activity. |
| DrugBank Pharmacology: | Pseudoephedrine causes vasoconstriction which leads to a decongestant effect. It has a short duration of action unless formulated as an extended release product. Patients should be counselled regarding the risk of central nervous system stimulation. |
| DrugBank MoA: | Pseudoephedrine acts mainly as an agonist of alpha adrenergic receptors and less strongly as an agonist of beta adrenergic receptors. This agonism of adrenergic receptors produces vasoconstriction which is used as a decongestant and as a treatment of priapism. Pseudoephedrine is also an inhibitor of norepinephrine, dopamine, and serotonin transporters. The sympathomimetic effects of pseudoephedrine include an increase in mean arterial pressure, heart rate, and chronotropic response of the right atria. Pseudoephedrine is also a partial agonist of the anococcygeal muscle. Pseudoephedrine also inhibits NF-kappa-B, NFAT, and AP-1. |
| Targets: | Sodium-dependent noradrenaline transporter inhibitor; Sodium-dependent dopamine transporter inhibitor; Alpha-1A adrenergic receptor agonist; Alpha-2A adrenergic receptor agonist; Sodium-dependent serotonin transporter inhibitor; Beta-2 adrenergic receptor partial agonist; Beta-1 adrenergic receptor agonist&partial agonist; Nuclear factor of activated T-cells, cytoplasmic 1 inhibitor; Tumor necrosis factor inhibitor; Nuclear factor NF-kappa-B p105 subunit inhibitor; activator protein 1 inhibitor; Interleukin-2 inhibitor |
| Inclusion Criteria: | Target associated |
